A new treatment option is more effective than tamoxifen at preventing a return of breast cancer in young women, according to the results of two international trials released Sunday.
Jun 1, 2014
0
0
A drug that has been shown to prevent breast cancer in postmenopausal women at high risk of developing the disease, and is poised for widespread use, appears to significantly worsen age-related bone loss, according to an ...
Feb 6, 2012
0
0
Results from a phase III clinical trial have shown that combining two existing cancer drugs to treat post-menopausal women with advanced breast cancer resistant to hormonal therapy significantly improves outcome. Researchers ...
Sep 26, 2011
0
0
Stockholm, Sweden: Women diagnosed with breast cancer late in life are at greater risk of dying from the disease than younger patients, assuming they survive other age-related conditions, according to a study to be presented ...
Sep 22, 2011
0
0
Exemestane steadily lowered levels of "good" cholesterol in women taking the agent as part of a breast cancer prevention study, say researchers at Georgetown Lombardi Comprehensive Cancer Center. Exemestane, an aromatase ...
Dec 9, 2011
0
0
Among postmenopausal women with hormone receptor-positive breast cancer, increasing age was associated with a higher risk of death from breast cancer, according to a study in the February 8 issue of JAMA.
Feb 7, 2012
0
0
(HealthDay)—Women at high risk of breast cancer should discuss with their doctors the use of so-called chemopreventive drugs to reduce that risk, according to a new practice guideline issued by the American Society of Clinical ...
Jul 9, 2013
0
0
(HealthDay)—The addition of ovarian suppression to tamoxifen is associated with increased survival versus tamoxifen alone among premenopausal women with breast cancer, according to a study published online June 4 in the ...
Jun 5, 2018
0
1
Results from a phase III clinical trial evaluating a new treatment for breast cancer in post-menopausal women show that the combination of two cancer drugs, everolimus and exemestane, significantly improves bone strength ...
Mar 23, 2012
0
0
(HealthDay) -- Afinitor (everolimus) has been approved in combination with the drug exemestane to treat postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer, the U.S. Food and Drug Administration ...
Jul 23, 2012
0
0
Exemestane (trade name Aromasin) is a drug used to treat breast cancer. It is a member of the class of drugs known as aromatase inhibitors. Some breast cancers require estrogen to grow. Those cancers have estrogen receptors (ERs), and are called ER-positive. They may also be called estrogen-responsive, hormonally-responsive, or hormone-receptor-positive. Aromatase is an enzyme that synthesizes estrogen. Aromatase inhibitors block the synthesis of estrogen. This lowers the estrogen level, and slows the growth of cancers.
This text uses material from Wikipedia, licensed under CC BY-SA
